Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors

Hiren Patel; Irina Chuckowree; Peter Coxhead; Matthew Guille; Minghua Wang; Alexandra Zuckermann; Robin Williams; Mariangela Librizzi; Ronald M. Paranal; James E. Bradner; John Spencer

doi:10.1039/c4md00211c

Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors

Hiren Patel, Irina Chuckowree, Peter Coxhead, Matthew Guille, Minghua Wang, Alexandra Zuckermann, Robin Williams, Mariangela Librizzi, Ronald M. Paranal, James E. Bradner, John Spencer

Research output: Contribution to journal › Article › peer-review

Abstract

Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2 inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)-N8-hydroxyoctanediamide 6.

Original language	English
Pages (from-to)	1829-1833
Number of pages	5
Journal	MedChemComm
Volume	12
DOIs	https://doi.org/10.1039/c4md00211c
Publication status	Published - 1 Dec 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/c4md00211c

Cite this

@article{ae994297d3214d9bad2e9f475312726c,

title = "Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors",

abstract = "Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2 inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)-N8-hydroxyoctanediamide 6.",

author = "Hiren Patel and Irina Chuckowree and Peter Coxhead and Matthew Guille and Minghua Wang and Alexandra Zuckermann and Robin Williams and Mariangela Librizzi and Paranal, {Ronald M.} and Bradner, {James E.} and John Spencer",

year = "2014",

month = dec,

day = "1",

doi = "10.1039/c4md00211c",

language = "English",

volume = "12",

pages = "1829--1833",

journal = "MedChemComm",

issn = "2040-2503",

publisher = "Royal Society of Chemistry",

}

TY - JOUR

T1 - Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors

AU - Patel, Hiren

AU - Chuckowree, Irina

AU - Coxhead, Peter

AU - Guille, Matthew

AU - Wang, Minghua

AU - Zuckermann, Alexandra

AU - Williams, Robin

AU - Librizzi, Mariangela

AU - Paranal, Ronald M.

AU - Bradner, James E.

AU - Spencer, John

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2 inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)-N8-hydroxyoctanediamide 6.

AB - Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2 inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)-N8-hydroxyoctanediamide 6.

U2 - 10.1039/c4md00211c

DO - 10.1039/c4md00211c

M3 - Article

SN - 2040-2503

VL - 12

SP - 1829

EP - 1833

JO - MedChemComm

JF - MedChemComm

ER -